DNTH - Dianthus Therapeutics, Inc. /DE/

QQQ $ 629.16 $ 3.02 (0.48 %)

DIA $ 475.58 $ 0.66 (0.14 %)

SPY $ 681.80 $ 2.23 (0.33 %)

TLT $ 90.21 $ -0.27 (-0.3 %)

GLD $ 368.20 $ -2.01 (-0.54 %)

Previous Close

$ 34.98

Open

$ 33.75

Bid

$ 27.50 x 12

Ask

$ 36.00 x 5

Day's Range

$ 33.43 - $ 35.26

52 Week Range

$ 13.37 - $ 40.16

Volume

322,819

Average Volume

Market Cap

1.13B

Beta (5Y Monthly)

$ 0.91

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-12-2025	03-31-2025	10-Q
3	03-11-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-21-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-23-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-08-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	03-03-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-03-2020	12-31-2019	10-K
24	11-13-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	03-19-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Dianthus Therapeutics Reviews New Data Fro...
10/29/2025 19:32:23

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label ex...

Dianthus Therapeutics Signs Exclusive Lice...
10/16/2025 11:07:09

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon producti...

Truist Securities Initiates Coverage On Di...
10/14/2025 13:07:14

Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and ann...

Clear Street Initiates Coverage On Dianthu...
09/17/2025 13:45:43

Clear Street analyst Bill Maughan initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces ...

Stifel Maintains Buy on Dianthus Therapeut...
09/12/2025 14:32:39

Stifel analyst Alex Thompson maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $52 t...

general-motors-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-friday

General Motors To Rally More Than 24%? Her...
09/12/2025 13:29:52

Wedbush Maintains Outperform on Dianthus T...
09/12/2025 12:10:21

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from...

3-biotech-stocks-showing-strength-with-big-spikes-in-momentum-scores

3 Biotech Stocks Showing Strength With Big...
09/12/2025 09:27:00

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Reported Earlier, Dianthus Therapeutics Pr...
09/10/2025 06:59:20

Raymond James Reiterates Outperform on Dia...
09/09/2025 15:09:38

Raymond James analyst Steven Seedhouse reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price...

Analyst Expectations For Dianthus Therapeu...
09/09/2025 14:01:07

Guggenheim Maintains Buy on Dianthus Thera...
09/09/2025 13:02:33

Guggenheim analyst Yatin Suneja maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $9...

Baird Maintains Outperform on Dianthus The...
09/09/2025 11:40:13

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $...

Dianthus Therapeutics Announces Proposed $...
09/08/2025 20:01:10

Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

dianthus-scores-early-success-analyst-boosts-confidence-in-broader-drug-pipeline

Dianthus Scores Early Success, Analyst Boo...
09/08/2025 14:42:22

Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 Ma...

HC Wainwright & Co. Reiterates Buy on Dian...
09/08/2025 12:16:30

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintai...

12 Health Care Stocks Moving In Monday's P...
09/08/2025 12:08:53

Trading Halt: Halt status updated at 7:25:...
09/08/2025 11:25:08

Dianthus Therapeutics Announces Clasepruba...
09/08/2025 11:08:45

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasth...

Trading Halt: Halted at 6:55:00 a.m. ET - ...
09/08/2025 10:55:04